Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q4 2016 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. The transcript is about General Mills' earnings call. They discuss various businesses, but the question is about deals, orders, contracts, projects, customers, sites, or programs. The company is a consumer packaged goods company. They talk about product launches, renovations, acquisitions, etc. But the specific phenomenon: "successive engagements of the same kind are coming in at progressively larger size" — meaning each new instance of essentially the same business is worth more than the last. For example, larger orders, bigger contracts, etc. Looking through the transcript, management discusses growth in various segments, but I don't see any mention of deal sizes escalating. They talk about organic sales growth, cost savings, margin expansion, portfolio segmentation. They mention acquisitions like EPIC Provisions, Carolina yogurt, etc., but not about the size of deals increasing over time. They talk about product launches like Tiny Toast, Annie's cereals, etc., but not about the scale of those launches being larger than previous ones. They mention distribution gains, but not about the size of individual orders or contracts. The question is very specific: "successive engagements of the same kind are coming in at progressively larger size" — that is, the company's own repeatable business is escalating in unit size. There is no such description in the transcript. Management does not talk about the size of orders, contracts, or projects increasing. They talk about volume growth, but not about the size of each engagement. Thus, the answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.